Ruboxistaurin,a Protein Kinase C β Inhibitor,as an Emerging Treatment for Diabetes Microvascular Complications

Abstract

French

OBJECTIVE:

To review current clinical data regarding the pharmacologic actions of ruboxistaurin (LY333531) mesylate, an inhibitor of protein kinase C (PKC) β, and its role to potentially reduce the development and/or the progression of diabetic microvascular complications.

DATA SOURCES:

Primary literature was obtained via a MEDLINE search (1966–August 2004) and through review of pertinent abstracts and presentations at major medical meetings.

STUDY SELECTION AND DATA EXTRACTION:

Literature relevant to PKC physiology, the pharmacokinetics of ruboxistaurin, and data evaluating the use of ruboxistaurin in treating diabetic microvascular complications in human and relevant animal models was reviewed.

DATA SYNTHESIS:

PKC is part of a group of intracellular signaling molecules activated in response to various specific hormonal, neuronal, and growth factor stimuli. Hyperglycemia leads to PKC β 1 and 2 isoform activation, which experimentally has been shown to contribute to the development and progression of diabetic microvascular complications (retinopathy, nephropathy, neuropathy) through various biochemical mechanisms. Animal and/or human studies using ruboxistaurin mesylate, a novel, highly selective inhibitor of PKC β, have shown delay in the progression and, in some cases, reversal of diabetic retinopathy, nephropathy, and neuropathy.

CONCLUSIONS:

Ruboxistaurin mesylate, by inhibiting excessive activation of certain PKC isoforms, has the potential to reduce the burden of microvascular complications for patients with diabetes.

Keywords

diabetic microvascular complications LY333531 protein kinase C ruboxistaurin.

Get full access to this article

View all access options for this article.

References

King

Aubert

Herman

. Global burden of diabetes, 1995–2005: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 14131.

Ruigomez

Garcia Rodriguez

. Presence of diabetes related complications at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998; 14: 439–45.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–63.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.

Way

Katai

King

. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18: 945–59.

Xia

Inoguchi

Kern

Engerman

Oates

King

. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994; 43: 1122–9.

Sheetz

King

. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579–88.

Nishikawa

Edelstein

Yamagishi

Matsumura

Kaneda

, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787–90.

Edelstein

Rossetti

Fantus

Goldberg

Ziyadeh

, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000; 97: 12222–6.

10.

Way

Chou

King

. Identification of PKC-isoform–specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000; 21: 181–7.

11.

Ohno

Nishizuka

. Protein kinase C isotypes and their specific functions: prologue. J Biochem 2002; 132: 509–11.

12.

Dutil

Newton

. Dual role of pseudosubstrate in the coordinated regulation of protein kinase C by phosphorylation and diacylglycerol. J Biol Chem 2000; 275: 10697–701.

13.

Idris

Gray

Donnelly

. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complication in diabetes. Diabetologia 2001; 44: 659–73.

14.

Liu

Heckman

. The sevenfold way of PKC regulation. Cell Signal 1998; 10: 529–42.

15.

Tomlinson

. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999;42: 1271–81.

16.

Wolf

Williamson

Easom

Chang

Sherman

Turk

. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. J Clin Invest 1991; 87: 31–8.

17.

Scivittaro

Ganz

Weiss

. AGEs induce oxidative stress and activate protein kinase C-beta (II) in neonatal mesangial cells. Am J Physiol Renal Physiol 2000; 278: F676–83.

18.

Aronson

Rayfield

. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 1: 1.

19.

Burkey

Campanale

O'Bannon

Cramer

Farid

. Disposition of LY333531, a selective protein kinase C beta inhibitor, in the Fischer 344 rat and beagle dog. Xenobiotica 2002; 32: 1045–52.

20.

Ring

Gillespie

Binkley

Campanale

Wrighton

. The interaction of a selective protein kinase C beta inhibitor with the human cytochrome P450. Drug Metab Dispos 2002; 30: 957–61.

21.

Demolle

DeSuray

Onkelinx

. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC β inhibitor, in healthy subjects (abstract). Clin Pharmacol Ther 1999; 65: 189.

22.

Kempen

O'Colmain

Leske

Haffner

Klein

Moss

, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552–63.

23.

Klein

BEK

Moss

Davis

DeMets

. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520–6.

24.

Ishii

Koya

King

. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998; 76: 21–31.

25.

Koya

King

. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859–66.

26.

Frank

. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002; 133: 693–8.

27.

Witmer

Vrensen

Van Noorden

Schlingemann

. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1–29.

28.

Yokota

Park J

Isshiki

Sotiropoulos

Rauniyar

, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003; 52: 838–45.

29.

Ishii

Jirousek

Koya

Takagi

Xia

Clermont

, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728–31.

30.

Xia

Aiello

L P

Ishii

Jiang Z

Park

Robinson

, et al. Characterization of vascular endothelial growth factors effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018–26.

31.

Danis

Bingaman

Jirousek

Yang

. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC β inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171–9.

32.

Suzuma

Takahara

Suzuma

Isshiki

Ueki

Leitges

, et al. Characterization of protein kinase C β isoforms action on retinoblastoma protein phosphorylation, vascular endothelial growth factor–induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 2002; 99: 721–6.

33.

Aiello

Bursell

Devries

. Protein kinase C β selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes (abstract). Diabetes 1999; 48: A19.

34.

Aiello

. Medical and pharmacologic treatment of diabetic macular edema. Presented at: The American Academy of Ophthalmology: Retina Subspecialty Days. Anaheim, CA, November 15–18, 2003.

35.

The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C beta inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54: 2188–97.

36.

Donnelly

Idris

Forrester

J V

. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88: 145–51.

37.

Duby

Campbell

Setter

White

Rasmussen

. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004; 61: 160–76.

38.

Vinik

Park

Stansberry

Pittenger

. Diabetic neuropathies. Diabetologia 2000; 43: 957–73.

39.

Cameron

Eaton

Cotter

Tesfaye

. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973–88.

40.

Vileikyte

Peyrot

Bundy

Rubin

Leventhal

Mora

, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003; 26: 2549–55.

41.

Ziegler

. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Rev 1999; 7: 342–57.

42.

Vinik

Erbas

. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001; 68: 928–44.

43.

Vinik

Erbas

Stansberry

. Gastrointestinal, genitourinary, and neurovascular disturbances in diabetes. Diabetes Rev 1999; 7: 3758–81.

44.

Perkins

Olaleye

Zinman

Bril

. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250–6.

45.

Apelqvist

Bakker

van Houtum

Nabuurs-Franssen

. Schaper

. International consensus and practical guidelines on the management and prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2000; 16 (suppl 1): S84–92.

46.

Gianni

Dyck

. Basement membrane thickening and perocyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995; 37: 498–504.

47.

Britland

Young

Sharma

Clarke

. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes 1990; 39: 909–13.

48.

Timperley

Ward

Preston

Duckworth

O'Malley

. A reassessment of vascular factors in relation to intravascular coagulation. Diabetologia 1976; 12: 237–43.

49.

Eichberg

. Protein kinase C changes in diabetes: is the concept relevant to neuropathy? Int Rev Neurobiol 2002; 50: 61–82.

50.

Cameron

Cotter

Jack

Basso

Hohman

. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999; 42: 1120–30.

51.

Nakamura

Kato

Hamada

Nakayama

Chaya

Nakashima

, et al. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090–5.

52.

Litchy

Dyck

Tesfaye

Zhang

Bastyr

, The MBBQ Study Group. Diabetic peripheral neuropathy assessed by neurological examination and composite scores is improved with L333531 treatment. In: Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. San Francisco, CA, June 14–18, 2002. Poster 800-P. Diabetes 2002; 51:(suppl 2): A197.

53.

Vinik

Tesfaye

Zhang

Bastyr

, The MBBQ Study Group. LY3333531 treatment improves diabetic peripheral neuropathy with symptoms (abstract 321–OR). Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association. San Francisco, CA, June 14–18, 2002. Diabetes 2002;51(suppl):2.

54.

Mogensen

. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42: 263–85.

55.

Whiteside

Dlugosz

. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol 2002; 282: F975–80.

56.

Cooper

. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352: 213–9.

57.

Kang

Johnson

. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003; 12: 43–9.

58.

Bailey

Bottomley

Westwell

Pringle

Furness

Feehally

, et al. Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridization. J Clin Pathol 1999; 52: 735–8.

59.

Makino

Tanaka

Mukoyama

Sugawara

Mori

Muro

, et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1–selective antagonist. J Am Soc Nephrol 2002; 13: 1757–65.

60.

Dunlop

Clark

Mahadevan

Muggli

Larkins

. Production of hyaluronan by glomerular mesangial cells in response to fibronectin and platelet-derived growth factor. Kidney Int 1996; 50: 40–4.

61.

Tuttle

Anderson

. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibition. Am J Kidney Dis 2003; 42: 456–65.

62.

Koya

Haneda

Nakagawa

Isshiki

Sato

Maeda

, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439–47.

63.

Tuttle

Bakris

Toto

McGill

Anderson

. Effect of ruboxistaurin on albuminuria and GFR in persons with type 2 diabetes and nephropathy (abstract). Diabetes 2005; 54 (suppl 1): 223.